Genmab Management
Management criteria checks 3/4
Genmab's CEO is Jan G.J. de Winkel, appointed in Jun 2010, has a tenure of 13.92 years. total yearly compensation is DKK44.30M, comprised of 20.8% salary and 79.2% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth DKK1.18B. The average tenure of the management team and the board of directors is 7.3 years and 7.2 years respectively.
Key information
Jan G.J. de Winkel
Chief executive officer
kr.44.3m
Total compensation
CEO salary percentage | 20.8% |
CEO tenure | 13.9yrs |
CEO ownership | 0.9% |
Management average tenure | 7.3yrs |
Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Genmab A/S' (CPH:GMAB) Price In Tune With Earnings
Apr 02We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope
Mar 07Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings
Feb 21Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?
Nov 13Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?
Jun 19Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?
May 29With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case
Mar 18Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 27Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching
Dec 17Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?
Nov 29Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?
Aug 29CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | kr.5b |
Dec 31 2023 | kr.44m | kr.9m | kr.4b |
Sep 30 2023 | n/a | n/a | kr.4b |
Jun 30 2023 | n/a | n/a | kr.5b |
Mar 31 2023 | n/a | n/a | kr.5b |
Dec 31 2022 | kr.42m | kr.9m | kr.5b |
Sep 30 2022 | n/a | n/a | kr.6b |
Jun 30 2022 | n/a | n/a | kr.4b |
Mar 31 2022 | n/a | n/a | kr.2b |
Dec 31 2021 | kr.38m | kr.8m | kr.3b |
Sep 30 2021 | n/a | n/a | kr.3b |
Jun 30 2021 | n/a | n/a | kr.3b |
Mar 31 2021 | n/a | n/a | kr.6b |
Dec 31 2020 | kr.37m | kr.7m | kr.5b |
Sep 30 2020 | n/a | n/a | kr.6b |
Jun 30 2020 | n/a | n/a | kr.6b |
Mar 31 2020 | n/a | n/a | kr.2b |
Dec 31 2019 | kr.35m | kr.7m | kr.2b |
Sep 30 2019 | n/a | n/a | kr.2b |
Jun 30 2019 | n/a | n/a | kr.1b |
Mar 31 2019 | n/a | n/a | kr.1b |
Dec 31 2018 | kr.28m | kr.7m | kr.1b |
Sep 30 2018 | n/a | n/a | kr.1b |
Jun 30 2018 | n/a | n/a | kr.1b |
Mar 31 2018 | n/a | n/a | kr.1b |
Dec 31 2017 | kr.27m | kr.7m | kr.1b |
Compensation vs Market: Jan G.J.'s total compensation ($USD6.38M) is above average for companies of similar size in the Danish market ($USD4.19M).
Compensation vs Earnings: Jan G.J.'s compensation has been consistent with company performance over the past year.
CEO
Jan G.J. de Winkel (62 yo)
13.9yrs
Tenure
kr.44,300,000
Compensation
Dr. Jan G.J. van de Winkel, Ph.D. is Independent Director of HOOKIPA Pharma Inc. from 2023 and serves as Chairman of the Board since 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital M...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 13.9yrs | kr.44.30m | 0.94% DKK 1.2b | |
Executive VP & CFO | 4.2yrs | kr.19.60m | 0.011% DKK 13.6m | |
Executive VP & Chief Legal Officer | 14.3yrs | kr.10.10m | no data | |
Executive VP & Chief Strategy Officer | 10.3yrs | kr.8.90m | no data | |
Senior Director of Clinical Operations & Non-Independent Director | no data | kr.800.00k | 0.00060% DKK 755.1k | |
Executive VP | 3.2yrs | kr.19.80m | 0.0048% DKK 6.0m | |
Senior Director | no data | kr.1.10m | 0.00081% DKK 1.0m | |
Senior Director of Finance Japan & Non-Independent Director | no data | kr.800.00k | 0.00013% DKK 163.6k | |
Executive VP & COO | 4.2yrs | kr.19.00m | 0.0044% DKK 5.6m | |
Senior Director | no data | no data | no data | |
Executive VP & Chief People Officer | no data | no data | no data | |
Executive VP & Chief Development Officer | 7.3yrs | kr.22.00m | 0.014% DKK 17.0m |
7.3yrs
Average Tenure
50yo
Average Age
Experienced Management: GMAB's management team is seasoned and experienced (7.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Senior Director of Clinical Operations & Non-Independent Director | 2.3yrs | kr.800.00k | 0.00060% DKK 755.1k | |
Senior Director | 5.2yrs | kr.1.10m | 0.00081% DKK 1.0m | |
Senior Director of Finance Japan & Non-Independent Director | 2.3yrs | kr.800.00k | 0.00013% DKK 163.6k | |
Non-Independent Director | 20.5yrs | kr.1.70m | 0.014% DKK 18.1m | |
Independent Director | 2.2yrs | kr.1.90m | no data | |
Independent Chairman of the Board | 7.2yrs | kr.2.80m | 0.0089% DKK 11.2m | |
Independent Director | 7.2yrs | kr.1.50m | 0.0052% DKK 6.5m | |
Independent Deputy Chairman | 9.3yrs | kr.2.10m | 0.0075% DKK 9.4m | |
Independent Director | 9.3yrs | kr.1.50m | 0.0032% DKK 4.1m |
7.2yrs
Average Tenure
57yo
Average Age
Experienced Board: GMAB's board of directors are considered experienced (7.2 years average tenure).